CN100337644C - Chinese medicine for treating peptic ulcer and its prepn process - Google Patents
Chinese medicine for treating peptic ulcer and its prepn process Download PDFInfo
- Publication number
- CN100337644C CN100337644C CNB2005100370777A CN200510037077A CN100337644C CN 100337644 C CN100337644 C CN 100337644C CN B2005100370777 A CNB2005100370777 A CN B2005100370777A CN 200510037077 A CN200510037077 A CN 200510037077A CN 100337644 C CN100337644 C CN 100337644C
- Authority
- CN
- China
- Prior art keywords
- powder
- preparation
- peptic ulcer
- parts
- chinese patent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗消化性溃疡的中成药及其制备方法，它由红参、黄芪、三七、人工牛黄和珍珠层粉为原料药制成。本发明的中成药具有补气健脾、宁心安神、行气活血、消炎生肌的功效，可用于治疗胃、十二指肠球部溃疡、慢性胃炎等病症。The invention discloses a Chinese patent medicine for treating peptic ulcer and a preparation method thereof, which is prepared from red ginseng, astragalus root, notoginseng, artificial bezoar and nacre powder as raw materials. The Chinese patent medicine of the invention has the effects of invigorating qi and invigorating the spleen, calming the mind and calming the nerves, promoting qi and blood circulation, reducing inflammation and promoting granulation, and can be used for treating diseases such as gastric and duodenal ulcers, chronic gastritis and the like.
Description
技术领域technical field
本发明涉及治疗消化性溃疡的药物，尤其是一种治疗消化性溃疡的中成药及其制备方法。The invention relates to a medicine for treating peptic ulcer, in particular to a Chinese patent medicine for treating peptic ulcer and a preparation method thereof.
背景技术Background technique
中医学认为，溃疡病发生的原因主要包括：脾胃虚弱，饮食失调，情志所伤，邪气侵犯和药物损伤等。一般认为人类消化性溃疡病多由于胃粘膜损害因素(氢离子、胆汁、药物等)和防御因素(胃壁粘液，上皮细胞间紧密连接，胃粘膜血流及上皮细胞产生的前列腺素等)之间的相互作用，凡使攻击因子增强或粘膜防御功能减弱的因素都可能成为消化性溃疡的病因；双方力量的消长导致溃疡的发生或愈合。对溃疡病的药物治疗也和这两方面密切相关。曾有人统计，人群中约10％在一生中患有消化性溃疡病，由此可见消化性溃疡病是常见病，多发病。Traditional Chinese medicine believes that the causes of ulcer disease mainly include: weakness of the spleen and stomach, eating disorders, emotional injury, evil invasion and drug damage. It is generally believed that human peptic ulcer disease is mostly due to the relationship between gastric mucosal damage factors (hydrogen ions, bile, drugs, etc.) Any factor that enhances the attack factor or weakens the defense function of the mucosa may become the cause of peptic ulcer; the ebb and flow of the strength of both parties will lead to the occurrence or healing of the ulcer. The drug treatment of ulcer disease is also closely related to these two aspects. According to statistics, about 10% of the population suffers from peptic ulcer disease in their lifetime, which shows that peptic ulcer disease is a common disease and frequently-occurring disease.
发明内容Contents of the invention
本发明的目的是提供一种治疗消化性溃疡的中成药及其制备方法。The object of the present invention is to provide a Chinese patent medicine for treating peptic ulcer and its preparation method.
为达上述目的，本发明的一种治疗消化性溃疡的中成药是由下列重量份的原料药制成：For reaching above-mentioned purpose, a kind of Chinese patent medicine for the treatment of peptic ulcer of the present invention is to be made from the crude drug of following weight part:
黄芪700-1400份、红参粉20-40份、人工牛黄10-20份、三七70-140份、珍珠层粉100-200份。700-1400 parts of astragalus, 20-40 parts of red ginseng powder, 10-20 parts of artificial bezoar, 70-140 parts of Panax notoginseng, 100-200 parts of nacre powder.
本发明优选的方案是：所述各原料药的重量份为：The preferred scheme of the present invention is: the parts by weight of each bulk drug are:
黄芪756份、红参粉25份、人工牛黄13份、三七76份、珍珠层粉101份。756 parts of astragalus, 25 parts of red ginseng powder, 13 parts of artificial bezoar, 76 parts of Panax notoginseng, 101 parts of nacre powder.
中医学认为，溃疡病发生的原因主要包括：脾胃虚弱，饮食失调，情志所伤，邪气侵犯和药物损伤等。溃疡病以上腹部疼痛为主要症状，临床特点为慢性、周期性和规律性的上腹部疼痛，与饮食有关，制酸剂可缓解症状。人参、黄芪补气健脾，益胃生肌为君药；三七配合参芪补气通脉，行气活血止痛为臣药；人工牛黄、珍珠层粉清热消炎，收敛生肌，制酸止痛，珍珠层粉质重镇，性味咸寒，与君药人参配合，能宁心安神定惊，人工牛黄、珍珠层粉二药共为佐药。诸药配合，具有补气健脾、宁心安神、行气活血、消炎生肌的功效，对于脾气虚弱兼有瘀热引起的胃脘痛，具有较好的疗效。Traditional Chinese medicine believes that the causes of ulcer disease mainly include: weakness of the spleen and stomach, eating disorders, emotional injury, evil invasion and drug damage. Upper abdominal pain is the main symptom of ulcer disease, and the clinical characteristics are chronic, periodic and regular upper abdominal pain, which is related to diet, and antacids can relieve symptoms. Ginseng and astragalus nourish qi and invigorate the spleen, benefit the stomach and promote granulation as the monarch drug; Panax notoginseng and ginseng invigorate qi and unblock the meridians, promote qi, activate blood and relieve pain as the minister drug; artificial bezoar and pearl layer powder clear heat and reduce inflammation, astringe and promote muscle growth, suppress acid and relieve pain , nacre powder is important, salty and cold in nature and taste, and combined with the monarch drug ginseng, it can calm the mind, calm the nerves and calm convulsions, artificial bezoar and nacre powder are adjuvant drugs. The combination of various medicines has the effects of invigorating qi and invigorating the spleen, calming the mind and calming the nerves, promoting qi and blood circulation, reducing inflammation and promoting granulation, and has a good curative effect on epigastric pain caused by spleen deficiency and blood stasis.
本发明药物的制备方法包括下列步骤：The preparation method of medicine of the present invention comprises the following steps:
a)在黄芪、红参粉、人工牛黄、三七和珍珠层粉五味药材中，取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；a) Among the five medicinal materials of astragalus, red ginseng powder, artificial bezoar, panax notoginseng and nacre powder, take astragalus and add water to decoct twice, the first time for 3 hours, the second time for 2 hours, filter, combine the filtrates, and concentrate into Thick paste;
b)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120细粉，过筛；b) The thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 fine powder, and sieved;
c)用配研法加入人工牛黄，混合均匀，得到药粉。c) adding artificial bezoar by compounding method, mixing evenly to obtain medicinal powder.
以下分别说明各种常用剂型的制剂过程：The preparation process of various commonly used dosage forms is explained respectively as follows:
(1)丸剂的制备：取得到的药粉，水泛为丸，干燥，原色打光，制成丸剂。(1) Preparation of pills: the obtained medicinal powder is flooded into pills, dried, polished in primary color, and made into pills.
(2)胶囊剂的制备：取得到的药粉，加入1％的羧甲基纤维素钠，混匀、制粒、充填，制成胶囊剂。(2) Preparation of capsules: add 1% sodium carboxymethylcellulose to the obtained medicinal powder, mix, granulate, and fill to make capsules.
(3)片剂的制备：取得到的药粉，拌入0.5％硬脂酸，压成片剂。(3) Preparation of tablets: the obtained medicinal powder was mixed with 0.5% stearic acid, and pressed into tablets.
(4)颗粒剂的制备：取得到的药粉，加入适量糊精，混匀、制成颗粒剂。(4) Preparation of granules: Add appropriate amount of dextrin to the obtained medicinal powder, mix well, and make granules.
(5)软胶囊剂的制备：取得到的药粉，加入等量的聚乙二醇-400和少量的丙三醇，混匀，压制成软胶囊剂。(5) Preparation of soft capsules: add an equal amount of polyethylene glycol-400 and a small amount of glycerol to the obtained medicinal powder, mix well, and press into soft capsules.
(6)散剂的制备：取得到的药粉，直接制成散剂。(6) Preparation of powder: the obtained powder is directly made into powder.
本发明优点是：它具有补气健脾、宁心安神、行气活血、消炎生肌的功效。以下通过一些实验数据，说明本发明制剂的治疗效果。The invention has the advantages of invigorating qi and invigorating the spleen, calming the mind and calming the nerves, promoting qi and blood circulation, reducing inflammation and promoting granulation. The therapeutic effect of the preparation of the present invention is illustrated below through some experimental data.
1、药效学实验结果表明：1. The results of pharmacodynamic experiments show that:
(1)采用盐酸乙醇、消炎痛造成急性胃粘膜损伤模型观察本发明制剂的胃粘膜保护作用。本发明制剂(0.6g/kg、1.2g/kg)可使盐酸乙醇引起的急性胃粘膜损伤模型损伤指数明显减少(p＜0.01)；本发明制剂(1.2g/kg)可使消炎痛造成急性胃粘膜损伤模型损伤指数明显减少(p＜0.05)。提示本发明制剂有抗急性胃粘膜损伤作用。(1) Observing the gastric mucosa protection effect of the preparation of the present invention by adopting the model of acute gastric mucosal injury caused by hydrochloric acid ethanol and indomethacin. The preparation of the present invention (0.6g/kg, 1.2g/kg) can significantly reduce the damage index of the acute gastric mucosa injury model caused by ethanol hydrochloride (p<0.01); the preparation of the present invention (1.2g/kg) can make indomethacin cause acute The injury index of the gastric mucosal injury model was significantly reduced (p<0.05). It is suggested that the preparation of the present invention has anti-acute gastric mucosal injury effect.
表1、本发明制剂对盐酸乙醇大鼠胃粘膜损伤的保护作用
与蒸馏水组比较：*P＜0.05；**P＜0.01，以下如未特殊注明则表示意义相同。Compared with the distilled water group: *P<0.05; **P<0.01, unless otherwise specified, the meanings are the same.
表2、本发明制剂对消炎痛大鼠胃粘膜损伤的保护作用Table 2, the protective effect of the preparation of the present invention on gastric mucosal injury of indomethacin rats
(2)、采用幽门结扎法及乙酸法胃溃疡模型观察观察本发明制剂抗胃溃疡作用。本发明制剂(1.2g/kg)可使幽门结扎法大鼠胃溃疡指数明显降低(p＜0.05)，两个剂量(0.6g/kg、1.2g/kg)可使乙酸法胃溃疡痊合率明显提高(p＜0.05或0.01)。(2) Observe and observe the anti-gastric ulcer effect of the preparation of the present invention by pyloric ligation and acetic acid method. The preparation of the present invention (1.2g/kg) can significantly reduce the gastric ulcer index of pyloric ligation rats (p＜0.05), and two doses (0.6g/kg, 1.2g/kg) can make the gastric ulcer healing rate of acetic acid method Significantly improved (p<0.05 or 0.01).
表3、本发明制剂对大鼠幽门结扎法胃溃疡的预防作用Table 3, the preventive effect of the preparation of the present invention on rat pyloric ligation gastric ulcer
表4、本发明制剂对大鼠乙酸法胃溃疡的治疗作用
(3)、采用大鼠蛋清足肿胀法和小鼠腹腔毛细血管通透性法观察其抗急性炎症效果。本发明制剂组(0.6g/kg、1.2g/kg)使大鼠蛋清引起的足肿胀率明显少于模型组(p＜0.05或0.01)，本发明制剂(0.6g/kg、1.2g/kg、2.4g/kg)可使炎症模型小鼠腹腔毛细血管通透性明显减少(p＜0.01)。提示本发明制剂有抗急性炎症作用。(3) The anti-acute inflammation effect was observed by rat egg white foot swelling method and mouse peritoneal capillary permeability method. The preparation group of the present invention (0.6g/kg, 1.2g/kg) makes the paw swelling rate that rat egg white causes obviously less than model group (p＜0.05 or 0.01), preparation of the present invention (0.6g/kg, 1.2g/kg , 2.4g/kg) can significantly reduce the peritoneal capillary permeability of inflammation model mice (p<0.01). It is suggested that the preparation of the present invention has anti-acute inflammation effect.
表5、本发明制剂对大鼠蛋清足肿胀的作用
与模型组比较：*P＜0.05；**P＜0.01。Compared with the model group: *P<0.05; **P<0.01.
表6、本发明制剂对小鼠腹腔毛细血管通透性的影响
(4)、采用离体肠管运动试验观察本发明制剂的解痉作用。结果表明本发明制剂对乙酰胆碱引起的家兔离体小肠及组织胺引起的豚鼠小肠强直性收缩有明显的拮抗作用，其作用随剂量的增加而加强。提示其有解痉作用。(4) The antispasmodic effect of the preparation of the present invention was observed by the isolated intestinal tract motility test. The results show that the preparation of the present invention has obvious antagonism to isolated rabbit small intestine caused by acetylcholine and tonic contraction of guinea pig small intestine caused by histamine, and the effect is strengthened with the increase of dose. Prompt its antispasmodic effect.
表7、本发明制剂对离体肠管运动的影响
注：括号内数为肠管数。※为浴管中药物浓度。Note: The numbers in brackets are the number of intestinal tubes. ※ is the drug concentration in the bath tube.
2、在广州中医药大学第一附属医院、广东省第二中医院、广州市中医院、福建省中医药研究院进行临床观察。共完成本发明制剂治疗胃脘痛临床研究409例，包括消化性溃疡265例，慢性浅表性胃炎144例。采用随机对照的研究方法，选用雷尼替丁胶囊作为对照药。观察结果表明：本发明制剂对消化性溃疡和慢性浅表性胃炎辨证属于脾胃虚弱兼有血瘀证型的疗效与对照药雷尼替丁胶囊相当，但在改善胃痛程度、胃痛时间、发作频率、纳呆、心悸气短等症状、体征方面，疗效优于对照组，差异有显著性意义。临床试验过程中，未见明显不良反应及不适症状。说明本发明制剂胶囊在临床上应用有效、安全。2. Conduct clinical observation in the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, the Second Hospital of Guangdong Province, Guangzhou Hospital of Traditional Chinese Medicine, and Fujian Academy of Traditional Chinese Medicine. A total of 409 cases of clinical research on the treatment of epigastric pain by the preparation of the present invention were completed, including 265 cases of peptic ulcer and 144 cases of chronic superficial gastritis. A randomized controlled study method was adopted, and ranitidine capsules were selected as the control drug. Observation result shows: the curative effect of preparation of the present invention to peptic ulcer and chronic superficial gastritis belong to spleen-stomach weakness combined with blood stasis syndrome is equivalent to that of contrast drug ranitidine capsule, but in improving stomachache degree, stomachache time, attack frequency , anorexia, palpitations, shortness of breath and other symptoms and signs, the curative effect was better than that of the control group, and the difference was significant. During the clinical trial, there were no obvious adverse reactions and discomfort symptoms. It shows that the preparation capsule of the present invention is effective and safe in clinical application.
具体实施方式Detailed ways
实施例1：本发明的药物的散剂制备方法：Embodiment 1: the powder preparation method of medicine of the present invention:
a)取黄芪756g、红参粉25g、人工牛黄13g、三七76g、珍珠层粉101g备用；a) Take astragalus 756g, red ginseng powder 25g, artificial bezoar 13g, Sanqi 76g, and nacre powder 101g for subsequent use;
b)取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；b) Take Astragalus and add water to decoct twice, the first time is 3 hours, the second time is 2 hours, filter, combine the filtrate, and concentrate into a thick paste;
c)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120目细粉，过筛；c) the thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 mesh fine powder, and sieved;
d)用配研法加入人工牛黄，混合均匀，得到药粉；d) adding artificial bezoar by compounding method, mixing uniformly to obtain medicated powder;
e)取得到的药粉，直接制成散剂。e) The obtained medicated powder is directly made into powder.
实施例2：本发明的药物的丸剂制备方法：Embodiment 2: the pill preparation method of medicine of the present invention:
a)取黄芪756g、红参粉25g、人工牛黄13g、三七76g、珍珠层粉101g备用；a) Take astragalus 756g, red ginseng powder 25g, artificial bezoar 13g, Sanqi 76g, and nacre powder 101g for subsequent use;
b)取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；b) Take Astragalus and add water to decoct twice, the first time is 3 hours, the second time is 2 hours, filter, combine the filtrate, and concentrate into a thick paste;
c)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120目细粉，过筛；c) the thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 mesh fine powder, and sieved;
d)用配研法加入人工牛黄，混合均匀，得到药粉；d) adding artificial bezoar by compounding method, mixing uniformly to obtain medicated powder;
e)取得到的药粉，水泛为丸，干燥，原色打光，制成丸剂。e) The obtained medicinal powder is flooded into pills, dried, polished in primary color, and made into pills.
实施例3：本发明的药物的胶囊剂制备方法：Embodiment 3: the capsule preparation method of medicine of the present invention:
a)取黄芪756g、红参粉25g、人工牛黄13g、三七76g、珍珠层粉101g备用；a) Take astragalus 756g, red ginseng powder 25g, artificial bezoar 13g, Sanqi 76g, and nacre powder 101g for subsequent use;
b)取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；b) Take Astragalus and add water to decoct twice, the first time is 3 hours, the second time is 2 hours, filter, combine the filtrate, and concentrate into a thick paste;
c)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120目细粉，过筛；c) the thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 mesh fine powder, and sieved;
d)用配研法加入人工牛黄，混合均匀，得到药粉；d) adding artificial bezoar by compounding method, mixing uniformly to obtain medicated powder;
e)取得到的药粉，加入1％的羧甲基纤维素钠，混匀、制粒、充填，制成胶囊剂。e) Add 1% sodium carboxymethylcellulose to the obtained medicinal powder, mix, granulate, and fill to make capsules.
实施例4：本发明的药物的片剂制备方法：Embodiment 4: the tablet preparation method of medicine of the present invention:
a)取黄芪756g、红参粉25g、人工牛黄13g、三七76g、珍珠层粉101g备用；a) Take astragalus 756g, red ginseng powder 25g, artificial bezoar 13g, Sanqi 76g, and nacre powder 101g for subsequent use;
b)取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；b) Take Astragalus and add water to decoct twice, the first time is 3 hours, the second time is 2 hours, filter, combine the filtrate, and concentrate into a thick paste;
c)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120目细粉，过筛；c) the thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 mesh fine powder, and sieved;
d)用配研法加入人工牛黄，混合均匀，得到药粉；d) adding artificial bezoar by compounding method, mixing uniformly to obtain medicated powder;
e)取得到的药粉，拌入0.5％硬脂酸，压成片剂。e) The obtained medicated powder is mixed with 0.5% stearic acid and pressed into tablets.
实施例5：本发明的药物的颗粒剂制备方法：Embodiment 5: the granule preparation method of medicine of the present invention:
a)取黄芪756g、红参粉25g、人工牛黄13g、三七76g、珍珠层粉101g备用；a) Take astragalus 756g, red ginseng powder 25g, artificial bezoar 13g, Sanqi 76g, and nacre powder 101g for subsequent use;
b)取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；b) Take Astragalus and add water to decoct twice, the first time is 3 hours, the second time is 2 hours, filter, combine the filtrate, and concentrate into a thick paste;
c)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120目细粉，过筛；c) the thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 mesh fine powder, and sieved;
d)用配研法加入人工牛黄，混合均匀，得到药粉；d) adding artificial bezoar by compounding method, mixing uniformly to obtain medicated powder;
e)取得到的药粉，加入适量糊精，混匀、制成颗粒剂。e) Add appropriate amount of dextrin to the obtained medicinal powder, mix well, and make granules.
实施例6：本发明的药物的软胶囊剂制备方法：Embodiment 6: the soft capsule preparation method of medicine of the present invention:
a)取黄芪756g、红参粉25g、人工牛黄13g、三七76g、珍珠层粉101g备用；a) Take astragalus 756g, red ginseng powder 25g, artificial bezoar 13g, Sanqi 76g, and nacre powder 101g for subsequent use;
b)取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；b) Take Astragalus and add water to decoct twice, the first time is 3 hours, the second time is 2 hours, filter, combine the filtrate, and concentrate into a thick paste;
c)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120目细粉，过筛；c) The thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 mesh fine powder, and sieved;
d)用配研法加入人工牛黄，混合均匀，得到药粉；d) adding artificial bezoar by compounding method, mixing uniformly to obtain medicated powder;
e)取得到的药粉，加入等量的聚乙二醇-400和少量的丙三醇，混匀，压制成软胶囊剂。e) Add an equal amount of polyethylene glycol-400 and a small amount of glycerol to the obtained medicinal powder, mix well, and press into soft capsules.
实施例7：本发明的药物的丸剂制备方法：Embodiment 7: the pill preparation method of medicine of the present invention:
a)取黄芪1400g、红参粉40g、人工牛黄20g、三七140g、珍珠层粉200g备用；a) Get astragalus 1400g, red ginseng powder 40g, artificial bezoar 20g, Panax notoginseng 140g, nacre powder 200g for subsequent use;
b)取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；b) Take Astragalus and add water to decoct twice, the first time is 3 hours, the second time is 2 hours, filter, combine the filtrate, and concentrate into a thick paste;
c)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120目细粉，过筛；c) the thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 mesh fine powder, and sieved;
d)用配研法加入人工牛黄，混合均匀，得到药粉；d) adding artificial bezoar by compounding method, mixing uniformly to obtain medicated powder;
e)得到的药粉，水泛为丸，干燥，原色打光，制成丸剂。e) The obtained medicinal powder is flooded into pills, dried, polished in primary color, and made into pills.
实施例8：本发明的药物的丸剂制备方法：Embodiment 8: the pill preparation method of medicine of the present invention:
a)取黄芪1100g、红参粉35g、人工牛黄15g、三七100g、珍珠层粉150g备用；a) Get astragalus 1100g, red ginseng powder 35g, artificial bezoar 15g, Panax notoginseng 100g, nacre powder 150g for subsequent use;
b)取黄芪加水煎煮两次，第一次3小时，第二次2小时，滤过，合并滤液，浓缩成稠膏；b) Take Astragalus and add water to decoct twice, the first time is 3 hours, the second time is 2 hours, filter, combine the filtrate, and concentrate into a thick paste;
c)稠膏与红参粉，三七粉，珍珠层粉混合均匀，干燥，粉碎成80-120目细粉，过筛；c) the thick paste is mixed evenly with red ginseng powder, Panax notoginseng powder and nacre powder, dried, crushed into 80-120 mesh fine powder, and sieved;
d)用配研法加入人工牛黄，混合均匀，得到药粉；d) adding artificial bezoar by compounding method, mixing uniformly to obtain medicated powder;
e)取得到的药粉，水泛为丸，干燥，原色打光，制成丸剂。e) The obtained medicinal powder is flooded into pills, dried, polished in primary color, and made into pills.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100370777A CN100337644C (en) | 2005-09-08 | 2005-09-08 | Chinese medicine for treating peptic ulcer and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100370777A CN100337644C (en) | 2005-09-08 | 2005-09-08 | Chinese medicine for treating peptic ulcer and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1739615A CN1739615A (en) | 2006-03-01 |
| CN100337644C true CN100337644C (en) | 2007-09-19 |
Family
ID=36092240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100370777A Expired - Lifetime CN100337644C (en) | 2005-09-08 | 2005-09-08 | Chinese medicine for treating peptic ulcer and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100337644C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078369A (en) * | 2011-01-20 | 2011-06-01 | 广州中一药业有限公司 | Application of Chinese patent drug for treating peptic ulcer in preparing alcohol resistance medicament |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565906B (en) * | 2012-07-30 | 2016-01-20 | 广州白云山中一药业有限公司 | Chinese patent medicine for the treatment of peptic ulcer and preparation method thereof |
| CN102772670B (en) * | 2012-08-17 | 2013-08-21 | 张守实 | Traditional Chinese medicine composition for treating superficial gastritis |
-
2005
- 2005-09-08 CN CNB2005100370777A patent/CN100337644C/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国卫生部药品标准第16册 中华人民共和国卫生部药典委员会，121 1998 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078369A (en) * | 2011-01-20 | 2011-06-01 | 广州中一药业有限公司 | Application of Chinese patent drug for treating peptic ulcer in preparing alcohol resistance medicament |
| CN102078369B (en) * | 2011-01-20 | 2012-06-06 | 广州中一药业有限公司 | Application of Chinese patent drug for treating peptic ulcer in preparing alcohol resistance medicament |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1739615A (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN100337644C (en) | Chinese medicine for treating peptic ulcer and its prepn process | |
| CN1739734A (en) | Traditional Chinese medicine preparation for treating oral inflammation and preparation method thereof | |
| CN1785367A (en) | Medicine for trenting flooding and spotting, haematemesis and homafecia | |
| CN1973878A (en) | Medicine for treating epigastric pain in children and preparation method thereof | |
| CN1741807A (en) | Anti-ulcer herbal composition | |
| CN1316990C (en) | Chinese medicinal composition, preparation method and quality control method thereof | |
| CN1966001A (en) | Medicament for treating inflammation and preparation method thereof | |
| CN1254267C (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN1465387A (en) | Chinese medicine preparation for treating carcinoma of esophagus | |
| CN1412202A (en) | Ganoderma applanatum polysaccharide, its preparation and medicine composition using said compound as active component | |
| CN1861184A (en) | Application of composition for preparing medicine to treat chilblain disease | |
| CN1164282C (en) | Tumor-treating medicine | |
| CN1049148C (en) | Stomach-recovering capsule | |
| CN1289139C (en) | Medicine for treating colitis and its preparing method | |
| CN1250237C (en) | Medicine combination containing white atractylodes rhizome and its preparation method | |
| CN1895322A (en) | Jinganmin effervescent tablets and preparation thereof | |
| CN1259949C (en) | Capsule for treating wound | |
| CN1864730A (en) | A cancer-treating medicine | |
| CN1213749C (en) | Prepn. of obakulactone contd. medicine for treating hemorrhoid, and its use | |
| CN101036681A (en) | Analgesic aconitum flavum | |
| CN1695657A (en) | Combination of medicine in use for treating ulcer in alimentary canal and preparation method | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1060659C (en) | Pill medicine for cancer and preparation method | |
| CN1147397A (en) | Chinese patent medicine for treating various cancers and tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: GUANGZHOU BAIYUNSHAN ZHONGYI PHARMACEUTICAL CO., L Free format text: FORMER NAME: GUANGZHOU ZHONGYI PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 510530, No. 32, Po pan Road, Guangzhou, Guangdong, Luogang District Patentee after: Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. Address before: 11, building 510620, west block, Times Square, 28 Tianhe North Road, Guangzhou, Guangdong Patentee before: Guangzhou Zhongyi Pharmaceutical Co., Ltd. |